Help accelerate clinical development with better MRD testing

Exquisite sensitivity and specificity for confident MRD detection. Interested in learning more about how Haystack MRD can support your clinical trials?

The clinical solution for MRD testing

Haystack MRD™ leverages exceptional sensitivity and specificity to accelerate clinical trials and produce insights that drive biopharma pipeline development.

previous arrow
Haystack MRD test
Treatment management
next arrow
Accurate ctDNA detection
The Haystack advantage

Haystack MRD’s technology enables ultrasensitive ctDNA testing with the ability to detect 95% of cases at 0.0005% tumor fraction, and in many cases, as low as 0.00008% tumor fraction, or approximately 1 ctDNA molecule in >1 million normal DNA molecules.

202405 Sensitivity rate
Confident MRD calls 1
Confident MRD calls

Haystack MRD delivers exceptional accuracy at ultra-low ctDNA levels. The test's clean background allows the calling threshold to be set lower than other methods, which yields the highest sensitivity for patient enrollment, stratification, and response monitoring.

Confident MRD calls 2
Confident MRD calls

Haystack MRD delivers exceptional accuracy at ultra-low ctDNA levels. The test's clean background allows the calling threshold to be set lower than other methods, which yields the highest sensitivity for patient enrollment, stratification, and response monitoring.

Multi-tool of MRD
The multi-tool of MRD

Unlike other tests, Haystack MRD was purpose-built for granular ctDNA testing that reports variant-level results. In addition to reporting sample-level MRD status, Haystack MRD can track specific ctDNA variants for various applications, including targeted therapy guidance.

Each patient’s whole genome library is also archived and is available for acquired resistance mapping and retrospective genomic discovery.

Get in touch

With our deep roots in liquid biopsy and MRD testing, Haystack Oncology is committed to providing biopharma solutions to improve patient outcomes. Let our exceptional MRD detection capabilities and team of global experts support your clinical cancer research and therapeutic development efforts.

Have questions? We would love to hear from you. Simply click the button below.

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Social: 

Visit Johns Hopkins School of Medicine to learn more.
Visit Johns Hopkins School of Medicine to learn more.
Visit Johns Hopkins School of Medicine to learn more.